Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

614
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
614
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

474
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
474
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

555
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
555

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perimetric Outcomes of Melbourne Rapid Field Perimetry in Patients With Glaucoma: A Systematic Review and Meta-Analysis.

Journal of glaucoma·2026
Same author

Locally-affiliated authorship in global eye health research conducted in Sub-Saharan Africa between 2003 and 2022.

Eye (London, England)·2026
Same author

Outcomes of Minimally Invasive Glaucoma Surgery, Trabeculectomy, and Tube Shunt Surgery in Secondary Glaucoma: IRIS® Registry Analysis.

American journal of ophthalmology·2026
Same author

Comparison of Glaucoma Surgery Incidence and Outcomes in Pigmentary and Primary Open-Angle Glaucoma: IRIS® Registry Analysis.

Ophthalmology·2026
Same author

Development of Perimetric Glaucoma and Outcomes of Interventions in Pseudoexfoliation Syndrome with and without Ocular Hypertension.

Ophthalmology·2026
Same author

Corneal Endothelial Keratoplasty After Glaucoma Treatment: An American Academy of Ophthalmology IRIS® Registry Analysis.

Ophthalmology. Glaucoma·2026
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jul 15, 2025

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.4K

Glaucoma: now and beyond.

Hari Jayaram1, Miriam Kolko2, David S Friedman3

  • 1Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK; UCL Institute of Ophthalmology, London, UK; National Institute for Health and Care Research Moorfields Biomedical Research Centre, London, UK.

Lancet (London, England)
|September 24, 2023
PubMed
Summary
This summary is machine-generated.

Glaucoma causes irreversible blindness by damaging retinal cells. Lowering intraocular pressure is key to slowing vision loss, but new treatments and early diagnosis are needed.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.4K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.1K

Related Experiment Videos

Last Updated: Jul 15, 2025

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.4K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.4K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.1K

Area of Science:

  • Ophthalmology
  • Neuroscience

Background:

  • Glaucoma is a leading cause of irreversible blindness.
  • It is characterized by progressive loss of retinal ganglion cells.
  • Elevated intraocular pressure is a key modifiable risk factor.

Purpose of the Study:

  • To review current understanding of glaucoma.
  • To highlight treatment modalities for lowering intraocular pressure.
  • To discuss diagnostic challenges and future research directions.

Main Methods:

  • Review of clinical trials and surgical innovations.
  • Analysis of diagnostic limitations and screening challenges.
  • Exploration of emerging research in neuroprotection and gene therapy.

Main Results:

  • Timely reduction of intraocular pressure effectively slows vision loss.
  • Many new surgical treatments lack robust clinical trial evidence.
  • Late diagnosis is common due to screening limitations.

Conclusions:

  • Effective glaucoma management relies on lowering intraocular pressure.
  • Further research is needed for intraocular pressure-independent treatments.
  • Personalized medicine and advanced therapies hold future promise.